TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).


Options:
A: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A
B: Arm Label: Cinacalcet; Type: EXPERIMENTAL; Interventions: Drug: Cinacalcet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: Other: Standard of care | Arm Label: Cinacalcet; Type: OTHER; Interventions: Drug: cinacalcet | Intervention Type: DRUG; Name: cinacalcet; Assigned to Arm(s): Cinacalcet | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care
D: Arm Label: IV Paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Cinacalcet (at sites with IV paricalcitol); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinacalcet | Arm Label: Oral paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Cinacalcet (at sites with oral paricalcitol); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cinacalcet | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): IV Paricalcitol, Oral paricalcitol | Intervention Type: DRUG; Name: Cinacalcet; Assigned to Arm(s): Cinacalcet (at sites with IV paricalcitol), Cinacalcet (at sites with oral paricalcitol)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).


Options:
A: Arm Label: Denosumab; Type: EXPERIMENTAL; Interventions: Drug: Denosumab (Prolia) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Denosumab (Prolia); Assigned to Arm(s): Denosumab
B: Intervention Type: DRUG; Name: Cinacalcet HCl; Assigned to Arm(s): N/A
C: Arm Label: Paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): Paricalcitol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
D: Arm Label: Parmidronate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Parmidronate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder
Brief Summary: The goals of this study are:

A. To determine whether olanzapine can help patients with bipolar disorder who currently have mild to moderate mania.

B. To assess the safety of olanzapine and any side effects that might be associated with it, as well as the quality of life and functioning of patients treated with olanzapine.

C. To assess how olanzapine compares to divalproex.


Options:
A: Intervention Type: DRUG; Name: divalproex sodium; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: divalproex sodium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Lithium (LI); Type: EXPERIMENTAL; Interventions: Drug: Lithium (LI) | Arm Label: Divalproex (DV); Type: EXPERIMENTAL; Interventions: Drug: Divalproex (DV) | Intervention Type: DRUG; Name: Lithium (LI); Assigned to Arm(s): Lithium (LI) | Intervention Type: DRUG; Name: Divalproex (DV); Assigned to Arm(s): Divalproex (DV)
D: Arm Label: Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: Divalproex sodium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Divalproex Sodium | Intervention Type: DRUG; Name: Divalproex Sodium; Assigned to Arm(s): Divalproex sodium | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #498 - Open Versus Endovascular Repair (OVER) Trial for Abdominal Aortic Aneurysms
Brief Summary: A multi-center, randomized clinical trial that will compare endovascular repair with standard open surgery in the repair of abdominal aortic aneurysms (AAA). Long and short-term results as well as the cost and quality of life associated with these two strategies for AAA repair will be compared.


Options:
A: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Open Repair | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Repair | Intervention Type: PROCEDURE; Name: Endovascular Repair; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Standard Open Repair; Assigned to Arm(s): Arm 1
B: Arm Label: OR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Aneurysm Repair | Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular Aneurysm Repair | Intervention Type: PROCEDURE; Name: Open Aneurysm Repair; Assigned to Arm(s): OR | Intervention Type: PROCEDURE; Name: Endovascular Aneurysm Repair; Assigned to Arm(s): EVAR
C: Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: EVAR (Endovascular repair of Abdominal Aortic aneurysm) | Arm Label: Surveillance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surveillance | Intervention Type: PROCEDURE; Name: EVAR (Endovascular repair of Abdominal Aortic aneurysm); Assigned to Arm(s): EVAR | Intervention Type: PROCEDURE; Name: Surveillance; Assigned to Arm(s): Surveillance
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #498 - Open Versus Endovascular Repair (OVER) Trial for Abdominal Aortic Aneurysms
Brief Summary: A multi-center, randomized clinical trial that will compare endovascular repair with standard open surgery in the repair of abdominal aortic aneurysms (AAA). Long and short-term results as well as the cost and quality of life associated with these two strategies for AAA repair will be compared.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Procedure: Endovascular repair | Arm Label: 2; Type: OTHER; Interventions: Procedure: Endovascular repair | Intervention Type: PROCEDURE; Name: Endovascular repair; Assigned to Arm(s): 1, 2
B: Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: EVAR (Endovascular repair of Abdominal Aortic aneurysm) | Arm Label: Surveillance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surveillance | Intervention Type: PROCEDURE; Name: EVAR (Endovascular repair of Abdominal Aortic aneurysm); Assigned to Arm(s): EVAR | Intervention Type: PROCEDURE; Name: Surveillance; Assigned to Arm(s): Surveillance
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open repair | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular repair (with endograft) | Intervention Type: PROCEDURE; Name: Endovascular repair (with endograft); Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Open repair; Assigned to Arm(s): 1
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Open Repair | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Repair | Intervention Type: PROCEDURE; Name: Endovascular Repair; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Standard Open Repair; Assigned to Arm(s): Arm 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #498 - Open Versus Endovascular Repair (OVER) Trial for Abdominal Aortic Aneurysms
Brief Summary: A multi-center, randomized clinical trial that will compare endovascular repair with standard open surgery in the repair of abdominal aortic aneurysms (AAA). Long and short-term results as well as the cost and quality of life associated with these two strategies for AAA repair will be compared.


Options:
A: Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: EVAR (Endovascular repair of Abdominal Aortic aneurysm) | Arm Label: Surveillance; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surveillance | Intervention Type: PROCEDURE; Name: EVAR (Endovascular repair of Abdominal Aortic aneurysm); Assigned to Arm(s): EVAR | Intervention Type: PROCEDURE; Name: Surveillance; Assigned to Arm(s): Surveillance
B: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard Open Repair | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Endovascular Repair | Intervention Type: PROCEDURE; Name: Endovascular Repair; Assigned to Arm(s): Arm 2 | Intervention Type: PROCEDURE; Name: Standard Open Repair; Assigned to Arm(s): Arm 1
C: Arm Label: Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early Endovascular Repair; Type: EXPERIMENTAL; Interventions: Device: AneuRx AAA stent graft / Talent AAA stent graft | Intervention Type: DEVICE; Name: AneuRx AAA stent graft / Talent AAA stent graft; Assigned to Arm(s): Early Endovascular Repair
D: Arm Label: OR; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Aneurysm Repair | Arm Label: EVAR; Type: EXPERIMENTAL; Interventions: Procedure: Endovascular Aneurysm Repair | Intervention Type: PROCEDURE; Name: Open Aneurysm Repair; Assigned to Arm(s): OR | Intervention Type: PROCEDURE; Name: Endovascular Aneurysm Repair; Assigned to Arm(s): EVAR

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Comparing Daily Atropine Versus Weekend Atropine
Brief Summary: The goals of this study are:

* To compare the visual acuity outcome in the amblyopic eye after 17 weeks of daily use of atropine versus weekend-only use of atropine.
* To compare the proportion of patients achieving a complete treatment response (defined as amblyopic eye acuity \>20/25 or equal to that of the sound eye in the absence of a reduction in the sound eye acuity from baseline) with daily atropine versus weekend-only atropine.


Options:
A: Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): N/A
B: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching
C: Intervention Type: DEVICE; Name: 6 hours occlusion by patching; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 12 hours occlusion by patching; Assigned to Arm(s): N/A
D: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Bangerter filters; Type: ACTIVE_COMPARATOR; Interventions: Device: Bangerter filters, Procedure: Near activities | Intervention Type: DEVICE; Name: Bangerter filters; Assigned to Arm(s): Bangerter filters | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Bangerter filters, Patching

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Comparing Daily Atropine Versus Weekend Atropine
Brief Summary: The goals of this study are:

* To compare the visual acuity outcome in the amblyopic eye after 17 weeks of daily use of atropine versus weekend-only use of atropine.
* To compare the proportion of patients achieving a complete treatment response (defined as amblyopic eye acuity \>20/25 or equal to that of the sound eye in the absence of a reduction in the sound eye acuity from baseline) with daily atropine versus weekend-only atropine.


Options:
A: Arm Label: I-BiT Plus; Type: EXPERIMENTAL; Interventions: Device: I-Bit plus | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: I-Bit plus; Assigned to Arm(s): I-BiT Plus
B: Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): N/A
C: Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Bangerter filters; Type: ACTIVE_COMPARATOR; Interventions: Device: Bangerter filters, Procedure: Near activities | Intervention Type: DEVICE; Name: Bangerter filters; Assigned to Arm(s): Bangerter filters | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Bangerter filters, Patching
D: Arm Label: Binocular Treatment; Type: EXPERIMENTAL; Interventions: Device: iPad® | Arm Label: Patching Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching 2 hours per day, 7 days per week | Intervention Type: DEVICE; Name: iPad®; Assigned to Arm(s): Binocular Treatment | Intervention Type: OTHER; Name: Patching 2 hours per day, 7 days per week; Assigned to Arm(s): Patching Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma
Brief Summary: The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an objective response (partial response/complete response \[PR/CR\]); 2) failed to demonstrate an objective response (PR/CR); or 3) could not tolerate such a regimen due to unacceptable toxicity. Patients will be randomized into one of three groups, and will receive one of the following treatments: MDX-010 alone, MDX-1379 alone, or MDX-010 in combination with MDX-1379.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
B: Arm Label: Dabrafenib and trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Dabrafenib and trametinib placebos; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib and trametinib | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Dabrafenib and trametinib placebos
C: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
D: Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma
Brief Summary: The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an objective response (partial response/complete response \[PR/CR\]); 2) failed to demonstrate an objective response (PR/CR); or 3) could not tolerate such a regimen due to unacceptable toxicity. Patients will be randomized into one of three groups, and will receive one of the following treatments: MDX-010 alone, MDX-1379 alone, or MDX-010 in combination with MDX-1379.


Options:
A: Arm Label: Biopsied Pigmented Skin Lesions; Type: OTHER; Interventions: Device: MelaFind(R) | Intervention Type: DEVICE; Name: MelaFind(R); Assigned to Arm(s): Biopsied Pigmented Skin Lesions
B: Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Placebo + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Ipilimumab, Drug: Placebo | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab, Placebo + Ipilimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Ipilimumab
C: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma
Brief Summary: The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an objective response (partial response/complete response \[PR/CR\]); 2) failed to demonstrate an objective response (PR/CR); or 3) could not tolerate such a regimen due to unacceptable toxicity. Patients will be randomized into one of three groups, and will receive one of the following treatments: MDX-010 alone, MDX-1379 alone, or MDX-010 in combination with MDX-1379.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
B: Arm Label: Arm A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm B Interferon 1 year; Type: EXPERIMENTAL; Interventions: Drug: Interferon-alpha2b - 1 year | Arm Label: Arm C Interferon 2 years; Type: EXPERIMENTAL; Interventions: Drug: Interferon-alpha2b - 2 years | Intervention Type: DRUG; Name: Interferon-alpha2b - 1 year; Assigned to Arm(s): Arm B Interferon 1 year | Intervention Type: DRUG; Name: Interferon-alpha2b - 2 years; Assigned to Arm(s): Arm C Interferon 2 years
C: Arm Label: observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: pegylated interferon alfa; Type: EXPERIMENTAL; Interventions: Biological: pegylated interferon alfa, Procedure: adjuvant therapy | Intervention Type: BIOLOGICAL; Name: pegylated interferon alfa; Assigned to Arm(s): pegylated interferon alfa | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): pegylated interferon alfa
D: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine

Answer: A